• Tidak ada hasil yang ditemukan

links.lww.com/CCM/D324

N/A
N/A
Protected

Academic year: 2024

Membagikan "links.lww.com/CCM/D324"

Copied!
2
0
0

Teks penuh

(1)

Supplemental Table 1. Identification of the predictors for adverse outcomes with logistic regression analysis Adverse Outcome

Death from any cause (n=8)

MACCE (n=14)

No obvious improvement of 1-year 3D LVEF (<6%) (n=13)

No improvement of 1-year angiogenesis (n=16)

Variables cHR 95% CI P-value cHR 95% CI P-value cHR 95% CI P-value cHR 95% CI P-value

Age (years) 0.98 (0.89,1.07) 0.583 0.97 (0.90,1.05) 0.513 0.97 (0.89,1.05) 0.415 0.98 (0.91,1.06) 0.608

Male gender 0.71 (0.14,3.65) 0.686 0.44 (0.11,1.81) 0.258 1.91 (0.40,9.02) 0.417 2.67 (0.58,12.36) 0.210 Body mass index 0.96 (0.77,1.20) 0.701 0.83 (0.66,1.03) 0.088 0.98 (0.81,1.17) 0.787 0.98 (0.82,1.17) 0.814 History or current smoking 1.50 (0.31,7.19) 0.612 1.05 (0.28,3.99) 0.943 0.44 (0.11,1.88) 0.271 2.57 (0.67,9.83) 0.168

Hypertension - - 0.999 1.86 (0.17,19.80) 0.608 - - 0.999 0.74 (0.09,5.89) 0.773

Diabetes mellitus 2.13 (0.22,20.41) 0.512 - - 0.999 0.98 (0.19,5.01) 0.981 - - 0.999

Dyslipidemia 0.19 (0.03,1.19) 0.076 0.38 (0.01,3.77) 0.329 0.87 (0.13,6.03) 0.886 0.72 (0.13,4.17) 0.716 Advanced CKD 0.67 (0.14,3.19) 0.612 1.53 (0.39,5.91) 0.543 2.70 (0.64,11.47) 0.178 0.62 (0.17,2.30) 0.470 Old stroke 1.67 (0.26,10.77) 0.592 2.80 (0.52,14.96) 0.228 0.62 (0.10,3.77) 0.602 2.00 (0.38,10.58) 0.415 Old myocardial infarction 3.29 (0.65,16.67) 0.151 0.97 (0.23,4.17) 0.969 3.86 (0.83,17.84) 0.085 1.14 (0.28,4.70) 0.860 Previous PCI 1.67 (0.34,8.26) 0.532 2.13 (0.55,8.26) 0.275 0.43 (0.11,1.76) 0.242 1.83 (0.49,6.90) 0.370 History of CABG 0.58 (0.01,3.36) 0.540 0.67 (0.16,2.77) 0.577 2.29 (0.54,9.63) 0.260 0.31 (0.07,1.41) 0.130 Hemoglobin (g/dL) 0.62 (0.35,1.09) 0.097 0.65 (0.41,1.03) 0.064 1.27 (0.82,1.98) 0.289 1.05 (0.70,1.57) 0.821 Serum creatinine (mg/dL) 3.87 (0.84,17.75) 0.082 2.43 (0.63,9.38) 0.198 4.01 (0.65,24.79) 0.135 1.64 (0.45,6.00) 0.458 Creatinine clearance rate (ml/min) 0.98 (0.94,1.02) 0.219 0.98 (0.95,1.01) 0.191 0.97 (0.94,1.01) 0.136 0.997 (0.97,1.03) 0.840 Total cholesterol (mg/dL) 0.997 (0.98,1.02) 0.774 0.993 (0.98,1.01) 0.425 0.98 (0.96,1.001) 0.065 1.001 (0.98,1.02) 0.944 Low density lipoprotein 0.996 (0.97,1.02) 0.708 0.99 (0.97,1.01) 0.389 0.99 (0.97,1.01) 0.244 0.996 (0.98,1.02) 0.709 High density lipoprotein 0.98 (0.91,1.06) 0.680 0.98 (0.91,1.04) 0.476 1.04 (0.97,1.11) 0.320 0.97 (0.91,1.04) 0.432 Triglyceride (mg/dL) 0.997 (0.99,1.01) 0.590 0.997 (0.99,1.01) 0.513 0.998 (0.99,1.01) 0.718 1.003 (0.994,1.01) 0.520 KDR+/CD34+/CD45- (%) 0.81 (0.36,1.83) 0.608 1.11 (0.73,1.69) 0.635 0.69 (0.27,1.76) 0.439 1.02 (0.67,1.55) 0.945 CD133+/CD34+/CD45- (%)

120.42

(0.13, 10880.36)

0.168 153.32

(0.17, 140952.65)

0.148 211.66

(0.20, 223471.43)

0.132

2.57 (0.01, 1351.96)

0.768

CD34+ (%) 0.67 (0.25,1.83) 0.437 0.91 (0.44,1.90) 0.809 1.09 (0.51,2.29) 0.831 1.16 (0.56,2.38) 0.694

(2)

Endothelial dysfunction - - 0.999 4.27 (0.78,23.53) 0.094 2.31 (0.49,10.82) 0.289 1.10 (0.27,4.43) 0.893 Left main stenosis (>50%) 1.33 (0.21,8.34) 0.758 2.00 (0.41,9.71) 0.390 2.82 (0.52,15.32) 0.231 0.36 (0.06,2.07) 0.251

Multi-vessel disease - - - -

Triple vessel disease - - 0.999 0.33 (0.05,2.30) 0.265 2.67 (0.26,26.86) 0.405 1.17 (0.17,7.96) 0.875

Number of vessel treated 0.35 (0.08,1.55) 0.168 1.20 (0.42,3.41) 0.736 1.08 (0.37,3.20) 0.886 1.40 (0.48,4.11) 0.542 Delivery of high-dose CD34+ cell 0.88 (0.18,4.17) 0.867 0.85 (0.23,3.17) 0.804 1.92 (0.48,7.77) 0.360 3.58 (0.90,14.15) 0.070

β-blocker 0.33 (0.05,2.45) 0.281 2.60 (0.26,25.93) 0.415 - - 0.999 1.17 (0.17,7.96) 0.875

ARB/ACEI 2.13 (0.22,20.41) 0.512 5.35 (0.58,49.10) 0.138 4.50 (0.48,42.50) 0.189 0.71 (0.15,3.40) 0.664

Statin 0.71 (0.14,3.65) 0.686 0.74 (0.18,3.02) 0.676 0.62 (0.14,3.1) 0.600 0.52 (0.13,2.17) 0.370

Abbreviations: MACCE, major adverse cardiac and cerebrovascular event; LVEF, left ventricular ejection fraction; cHR, crude hazard ratio; CI, confidence interval;

CKD, chronic kidney disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; EPC, endothelial progenitor cell;

ARB/ACEI, angiotensin II type I receptor blocker/angiotensin converting enzyme inhibitor

Referensi

Dokumen terkait